Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors Post author: Post published:March 1, 2026 Post category: Continue ReadingSafety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax Post author: Post published:March 1, 2026 Post category: Continue ReadingCirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) Post author: Post published:March 1, 2026 Post category: Continue ReadingIMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors Post author: Post published:March 1, 2026 Post category: Continue ReadingA Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors Post author: Post published:March 1, 2026 Post category: Continue ReadingFT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
Guselkumab (Anti-IL 23 Monoclonal Antibody) for Alcohol Associated Liver Disease Post author: Post published:March 1, 2026 Post category: Continue ReadingGuselkumab (Anti-IL 23 Monoclonal Antibody) for Alcohol Associated Liver Disease
